{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:27:56Z","timestamp":1773700076861,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>MicroRNAs (miRNAs) play crucial functions in the progression of ovarian cancer. MicroRNA-27b-5p (miR-27b-5p) has been identified as a cancer-associated miRNA. Nevertheless, the expression profile of miR-27b-5p and its functions in ovarian cancer are unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>qRT-PCR and western blot analysis were used to detect the levels of miR-27b-5p and C-X-C motif chemokine ligand 1 (CXCL1). The impact of miR-27b-5p on ovarian cancer cells proliferation, migration and invasion in vitro were investigated using Cell Counting Kit-8 (CCK8), wound healing and Transwell, respectively. The expression of matrix metalloprotein-2\/9 (MMP-2\/9) were measured using immunofluorescence staining. Bioinformatics and luciferase reporter analysis were used to predict the target of miR-27b-5p. The growth of ovarian cancer cells in vivo was evaluated using transplanted tumor model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here, we demonstrated that miR-27b-5p was downregulated in ovarian carcinoma cells and clinical specimens. Higher expression of miR-27b-5p was associated with an unfavorable overall survival in patients with ovarian cancer. Upregulation of miR-27b-5p decreased the viability, migration ability and invasion capacity of SKOV3 and OVCAR3 cell. MiR-27b-5p also inhibited the growth of SKOV3 cell in nude mice. Additionally, we verified that CXCL1 was a target of miR-27b-5p in ovarian carcinoma cells. Restoring the expression of CXCL1 abolished the inhibitory impacts of miR-27b-5p in ovarian cancer carcinoma cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This research revealed that miR-27b-5p restrained the progression of ovarian carcinoma possibly via targeting CXCL1.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-020-00697-6","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T06:05:33Z","timestamp":1597125933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Tumor-suppressor miRNA-27b-5p regulates the growth and metastatic behaviors of ovarian carcinoma cells by targeting CXCL1"],"prefix":"10.1186","volume":"13","author":[{"given":"Chun Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue Ning","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao Lan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan Yong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun Hong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"key":"697_CR1","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1111\/j.1582-4934.2010.01148.x","volume":"15","author":"O Vaksman","year":"2011","unstructured":"Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B. Reich R: miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med. 2011;15:1593\u2013602.","journal-title":"J Cell Mol Med"},{"key":"697_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.gene.2018.04.005","volume":"662","author":"VI Loginov","year":"2018","unstructured":"Loginov VI, Pronina IV, Burdennyy AM, Filippova EA, Kazubskaya TP, Kushlinsky DN, Utkin DO, Khodyrev DS, Kushlinskii NE, Dmitriev AA, Braga EA. Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis. Gene. 2018;662:28\u201336.","journal-title":"Gene"},{"key":"697_CR3","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.3892\/ol.2015.3610","volume":"10","author":"S Wei","year":"2015","unstructured":"Wei S, Wang Y, Xu H, Kuang Y. Screening of potential biomarkers for chemoresistant ovarian carcinoma with miRNA expression profiling data by bioinformatics approach. Oncol Lett. 2015;10:2427\u201331.","journal-title":"Oncol Lett"},{"key":"697_CR4","first-page":"1435","volume":"40","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Yokoi A, Kagawa T, Oda S, Hattori S, Tamauchi S, Ikeda Y, Yoshikawa N, Nishino K, Utsumi F, Niimi K, Suzuki S, Shibata K, Kajiyama H, Yokoi T, Kikkawa F. Unique miRNA profiling of squamous cell carcinoma arising from ovarian mature teratoma: comprehensive miRNA sequence analysis of its molecular background. Carcinogenesis. 2019;40:1435\u201344.","journal-title":"Carcinogenesis"},{"key":"697_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13046-016-0371-6","volume":"35","author":"B Tang","year":"2016","unstructured":"Tang B, Lei B, Qi G, Liang X, Tang F, Yuan S, Wang Z, Yu S, He S. MicroRNA-155-3p promotes hepatocellular carcinoma formation by suppressing FBXW7 expression. J Exp Clin Cancer Res. 2016;35:93.","journal-title":"J Exp Clin Cancer Res"},{"key":"697_CR6","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1038\/ncomms3977","volume":"5","author":"A Parikh","year":"2014","unstructured":"Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F, Mullokandov G, Fishman D, D'Incalci M, Rahaman J, Kalir T, Redline RW, Brown BD, Narla G. DiFeo a: microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun. 2014;5:2977.","journal-title":"Nat Commun"},{"key":"697_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185565","volume":"12","author":"F Xie","year":"2017","unstructured":"Xie F, Hosany S, Zhong S, Jiang Y, Zhang F, Lin L, Wang X, Gao S, Hu X. MicroRNA-193a inhibits breast cancer proliferation and metastasis by downregulating WT1. PLoS One. 2017;12:e0185565.","journal-title":"PLoS One"},{"key":"697_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10555-017-9712-y","volume":"37","author":"J Kim","year":"2018","unstructured":"Kim J, Yao F, Xiao Z, Sun Y, Ma L. MicroRNAs and metastasis: small RNAs play big roles. Cancer Metastasis Rev. 2018;37:5\u201315.","journal-title":"Cancer Metastasis Rev"},{"key":"697_CR9","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.7150\/thno.8712","volume":"4","author":"HJ Zhao","year":"2014","unstructured":"Zhao HJ, Ren LL, Wang ZH, Sun TT, Yu YN, Wang YC, Yan TT, Zou W, He J, Zhang Y, Hong J, Fang JY. MiR-194 deregulation contributes to colorectal carcinogenesis via targeting AKT2 pathway. Theranostics. 2014;4:1193\u2013208.","journal-title":"Theranostics"},{"key":"697_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12943-016-0533-3","volume":"15","author":"Z He","year":"2016","unstructured":"He Z, Yi J, Liu X, Chen J, Han S, Jin L, Chen L, Song H. MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial-mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma. Mol Cancer. 2016;15:51.","journal-title":"Mol Cancer"},{"key":"697_CR11","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1002\/2211-5463.12738","volume":"9","author":"Q Li","year":"2019","unstructured":"Li Q, Wu X, Guo L, Shi J, Li J. MicroRNA-7-5p induces cell growth inhibition, cell cycle arrest and apoptosis by targeting PAK2 in non-small cell lung cancer. FEBS Open Bio. 2019;9:1983\u201393.","journal-title":"FEBS Open Bio"},{"key":"697_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12943-017-0582-2","volume":"16","author":"CS Mak","year":"2017","unstructured":"Mak CS, Yung MM, Hui LM, Leung LL, Liang R, Chen K, Liu SS, Qin Y, Leung TH, Lee KF, Chan KK, Ngan HY, Chan DW. MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12\/Sp1\/survivin axis. Mol Cancer. 2017;16:11.","journal-title":"Mol Cancer"},{"key":"697_CR13","doi-asserted-by":"publisher","first-page":"7318","DOI":"10.1038\/ncomms8318","volume":"6","author":"RU Takahashi","year":"2015","unstructured":"Takahashi RU, Miyazaki H, Takeshita F, Yamamoto Y, Minoura K, Ono M, Kodaira M, Tamura K, Mori M, Ochiya T. Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1. Nat Commun. 2015;6:7318.","journal-title":"Nat Commun"},{"key":"697_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/cr.2015.23","volume":"25","author":"W Mu","year":"2015","unstructured":"Mu W, Hu C, Zhang H, Qu Z, Cen J, Qiu Z, Li C, Ren H, Li Y, He X, Shi X. Hui L: miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res. 2015;25:477\u201395.","journal-title":"Cell Res"},{"key":"697_CR15","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1261\/rna.059592.116","volume":"23","author":"W Liu","year":"2017","unstructured":"Liu W, Lv C, Zhang B, Zhou Q, Cao Z. MicroRNA-27b functions as a new inhibitor of ovarian cancer-mediated vasculogenic mimicry through suppression of VE-cadherin expression. RNA. 2017;23:1019\u201327.","journal-title":"RNA"},{"key":"697_CR16","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1677\/ERC-10-0107","volume":"17","author":"C Bolitho","year":"2010","unstructured":"Bolitho C, Hahn MA, Baxter RC, Marsh DJ. The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocr Relat Cancer. 2010;17:929\u201340.","journal-title":"Endocr Relat Cancer"},{"key":"697_CR17","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1002\/jcb.24191","volume":"113","author":"L Kavandi","year":"2012","unstructured":"Kavandi L, Collier MA, Nguyen H, Syed V. Progesterone and calcitriol attenuate inflammatory cytokines CXCL1 and CXCL2 in ovarian and endometrial cancer cells. J Cell Biochem. 2012;113:3143\u201352.","journal-title":"J Cell Biochem"},{"key":"697_CR18","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.biocel.2009.12.014","volume":"42","author":"WC Cho","year":"2010","unstructured":"Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42:1273\u201381.","journal-title":"Int J Biochem Cell Biol"},{"key":"697_CR19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.biopha.2017.07.005","volume":"93","author":"X Zhang","year":"2017","unstructured":"Zhang X, He X, Liu Y, Zhang H, Chen H, Guo S, Liang Y. MiR-101-3p inhibits the growth and metastasis of non-small cell lung cancer through blocking PI3K\/AKT signal pathway by targeting MALAT-1. Biomed Pharmacother. 2017;93:1065\u201373.","journal-title":"Biomed Pharmacother"},{"key":"697_CR20","first-page":"5602","volume":"21","author":"L Yang","year":"2017","unstructured":"Yang L, Hou J, Cui XH, Suo LN, Lv YW. MiR-133b regulates the expression of CTGF in epithelial-mesenchymal transition of ovarian cancer. Eur Rev Med Pharmacol Sci. 2017;21:5602\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"697_CR21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/cbf.3304","volume":"35","author":"KS Chandrasekaran","year":"2017","unstructured":"Chandrasekaran KS, Sathyanarayanan A. Karunagaran D: miR-214 activates TP53 but suppresses the expression of RELA, CTNNB1, and STAT3 in human cervical and colorectal cancer cells. Cell Biochem Funct. 2017;35:464\u201371.","journal-title":"Cell Biochem Funct"},{"key":"697_CR22","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/ijc.28086","volume":"133","author":"YM Yeh","year":"2013","unstructured":"Yeh YM, Chuang CM, Chao KC, Wang LH. MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1alpha. Int J Cancer. 2013;133:867\u201378.","journal-title":"Int J Cancer"},{"key":"697_CR23","first-page":"2341","volume":"24","author":"S Yang","year":"2019","unstructured":"Yang S, Yang R, Lin R, Si L. MicroRNA-375 inhibits the growth, drug sensitivity and metastasis of human ovarian cancer cells by targeting PAX2. J BUON. 2019;24:2341\u20136.","journal-title":"J BUON"},{"key":"697_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11010-013-1959-1","volume":"390","author":"L Wan","year":"2014","unstructured":"Wan L, Zhang L, Fan K, Wang J. MiR-27b targets LIMK1 to inhibit growth and invasion of NSCLC cells. Mol Cell Biochem. 2014;390:85\u201391.","journal-title":"Mol Cell Biochem"},{"key":"697_CR25","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1038\/onc.2011.543","volume":"31","author":"JJ Lee","year":"2012","unstructured":"Lee JJ, Drakaki A, Iliopoulos D, Struhl K. MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene. 2012;31:3818\u201325.","journal-title":"Oncogene"},{"key":"697_CR26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.5301\/JBM.2011.8616","volume":"26","author":"Q Wang","year":"2011","unstructured":"Wang Q, Li D, Zhang W, Tang B, Li QQ, Li L. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses. Int J Biol Markers. 2011;26:262\u201373.","journal-title":"Int J Biol Markers"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00697-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-020-00697-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00697-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T19:16:06Z","timestamp":1628622966000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-020-00697-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["697"],"URL":"https:\/\/doi.org\/10.1186\/s13048-020-00697-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-20826\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-20826\/v1","asserted-by":"object"}]},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,11]]},"assertion":[{"value":"2 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was approved by the Ethics Committee of Heze Municipal Hospital and in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained before this research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}